Mga Batayang Estadistika
| CIK | 892822 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Hemagen Diagnostics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| January 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 1-11700 HEMAGEN DIAGNOSTICS, INC. (Exact name of registrant as specified in |
|
| January 30, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K JANUARY 30, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2013 HEMAGEN DIAGNOSTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 1-11700 04-2869857 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 11, 2013 |
Exhibit 10.1 Hemagen Diagnostics, Inc. 9033 Red Branch Road Columbia, Maryland 21045 Phone 443 367 5500 Fax 410 997 7812 January 5, 2013 M. Robert Campbell 6412 Misty Top Pass Columbia, MD 21044 (410) 978-8838 [email protected] Bob, I am pleased to offer you the position of Chief Financial Officer, for Hemagen Diagnostics, Inc. In this role you will report directly to me and you will be |
|
| January 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2013 HEMAGEN DIAGNOSTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 1-11700 04-2869857 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 28, 2012 |
hem10k930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year ended September 30, 2012 Commission file number 1-11700 HEMAGEN DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 04-2869857 (State or Other Jurisdiction (I.R.S. emplo |
|
| December 28, 2012 |
EX-10.19 3 ex1019.htm EXHIBIT 10.19 Exhibit 10.19 |
|
| December 28, 2012 |
Exhibit 10.18 |
|
| August 14, 2012 |
Quarterly Report - HEMAGEN 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2012. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File No. 1-11700 HEMAGEN DIAGNOSTICS, INC. (Ex |
|
| July 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 6, 2012 HEMAGEN DIAGNOSTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 1-11700 04-2869857 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 31, 2012 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-171380 Prospectus HEMAGEN DIAGNOSTICS, INC. 11,571,023 Shares of Common Stock On September 30, 2009 we completed an exchange offer pursuant to which holders of 8% Senior Subordinated Secured Convertible Notes due 2009 exchanged those Notes for modified 8% Senior Subordinated Secured Convertible Notes due 2014. In this prospectus we refer to the |
|
| May 30, 2012 |
Hemagen Diagnostics, Inc. 9033 Red Branch Road Columbia, Maryland 21045 May 30, 2012 Via Edgar 1933 Act Filing Desk Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Registration Statement on Form S-3 Filed December 23, 2010 File No. 333-171380 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, the registrant named below hereby requests that th |
|
| May 22, 2012 |
Hemagen Diagnostics, Inc. 9033 Red Branch Road Columbia, MD 21045 Fax: (410) 797-7812 Via EDGAR May 22, 2012 Mr. Jeffrey P. Riedler Mr. Daniel Greenspan, Special Counsel Ms. Laura Crotty Securities and Exchange Commission Division of Corporation Finance Mail Stop 3720 100 F Street, N.E. Washington, D.C. 20549 Re: Hemagen Diagnostics, Inc. Registration Statement on Form S-3 Filed December 23, 2010 |
|
| May 22, 2012 |
As filed with the Securities and Exchange Commission on May 22, 2012 Registration No. |
|
| May 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2012. o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File No. 1-11700 HEMAGEN DIAGNOSTICS, INC. |
|
| March 30, 2012 |
CORRESP 1 filename1.htm Hemagen Diagnostics, Inc. 9033 Red Branch Road Columbia, MD 21045 Fax: (410) 797-7812 Via EDGAR March 30, 2012 Mr. Jeffrey P. Riedler Mr. Daniel Greenspan, Special Counsel Ms. Laura Crotty Securities and Exchange Commission Division of Corporation Finance Mail Stop 3720 100 F Street, N.E. Washington, D.C. 20549 Re: Hemagen Diagnostics, Inc. Registration Statement on Form S- |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2011. o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File No. 1-11700 HEMAGEN DIAGNOSTICS, IN |
|
| December 8, 2011 |
CORRESP 1 filename1.htm Hemagen Diagnostics, Inc. 9033 Red Branch Road Columbia, MD 21045 Fax: (410) 797-7812 Via EDGAR December 8, 2011 Mr. Jeffrey P. Riedler Mr. Daniel Greenspan, Special Counsel Ms. Laura Crotty Securities and Exchange Commission Division of Corporation Finance Mail Stop 3720 100 F Street, N.E. Washington, D.C. 20549 Re: Hemagen Diagnostics, Inc. Registration Statement on Form |
